Close
FINDING CURES TOGETHER<sup>SM</sup>

​​​​​​​​​Current ​MEG Announcements

MEG Special Conference 2019

"Modernizing Population Sciences in the Digital Age"
Feb. 19-22, 2019 | Hard Rock Hotel San Diego | San Diego, California

We anticipate a very stimulating special conference to focus on how to keep our research collaborative to the digital age. We look forward to your attendance at this exciting event that will provide up-to-date content as well as networking opportunities with your colleagues in epidemiology research.

Cancer Epidemiology, Biomarkers & Prevention (CEBP) announces its latest impact factor of 4.554 (Clarivate Analytics 2018)

The journal ranks 58th out of the 222 journals in the oncology category and 16th out of 336 journals in the public health category, according to impact factor.

CEBP thanks MEG members for their continued support and contributions. Please submit your papers to CEBP and take advantage of the special MEG discount (see info on this below).

Cancer Epidemology, Biomarkers & Prevention Editor-in-Chief Search Underway

MEG members, please note that your MEG journal, Cancer Epidemiology, Biomarkers & Prevention (CEBP) has initiated a search for editor-in-chief. For more information, please visit the CEBP website. The MEG Steering Committee extends its sincerest appreciation to the present EIC, Dr. Timothy R. Rebbeck. Dr. Rebbeck has provided excellent leadership and guidance to this exciting journal to the MEG community for many years, and has always encouraged a strong relationship between CEBP and the MEG Working Group. We wish him all the best in the future!

University of Nottingham, UK
Three-year fully funded Fellowships in Cancer Research

The University of Nottingham is investing in cancer research.  In 2019, a new £25 million purpose-built research building will open, providing state-of-the art research facilities and housing the newly established Centre for Cancer Sciences. The centre will bring together cancer researchers from around the university in one location to create a world class cancer research facility.

Visit our website for more information on how to apply for these fellowships, which will commence in September 2019. 
Deadline for Expressions of Interest: Oct. 12, 2018, 17:00 hours UK time
(12 noon US Eastern Time).

Request for Proposals for Genome-wide Investigation of Late-effects Using the Childhood Cancer Survivor Study (CCSS) Cohort

The Childhood Cancer Survivor Study (CCSS) is an NCI-funded resource for the study of long-term survivors of cancer diagnosed during childhood and adolescence. Learn the details regarding the cohort.

Members of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute and CCSS investigators collaborated to conduct a genome-wide association study, initially intended to study the role of genetic susceptibility in the development of subsequent neoplasms as well as first primary childhood cancers using samples from the CCSS Biorepository. Genotyping was conducted for 5739 childhood cancer survivors diagnosed 1970-1986 (5324 are of European ancestry) using the Illumina HumanOmni5Exome microarray, with over 4.1 million loci passing quality control thresholds (based on locus and sample missing rates, sample heterozygosity, and sex discrepancies).
 
The CCSS leadership is now broadening the scope of this initiative to study the role of genetic susceptibility in the development of non-malignant, treatment-related outcomes in cancer survivors. Accordingly, CCSS is announcing a request for proposals to collaborate with CCSS and NCI investigators in the use of existing genome-wide association study (GWAS) data and corresponding outcomes-related data to address innovative research questions relating to potential genetic contributions to risk for non-malignant treatment-related outcomes. Requests will be accepted on an ongoing basis and will be reviewed three times per year, in February, June, and October (cut-off for receipt of applications February 1, June 1, October 1). 
Learn more details regarding the application process as well as the application for data access.

From the Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute

The Epidemiology and Genomics Research Program in NCI’s Division of Cancer Control and Population Sciences invites AACR-MEG members to register for upcoming webinars.

To learn more about the EGRP's webinar series, visit the SeqSPACE Upcoming Topics and Speakers webpage.

MEG Members Receive an Additional 5 Percent Discount on CEBP Accepted Manuscripts

MEG members receive a special 5 percent discount for publication fees only (not AuthorChoice) for articles accepted in Cancer Epidemiology, Biomarkers & Prevention (CEBP). This is in addition to the 5 percent discount given to all AACR members-just use the code "MEGAO2018" when receiving notification from the CEBP staff about author billing. Thus, MEG members receive a total discount of 10 percent. See the information for authors for CEBP submissions. We look forward to receiving your submission.

CancerCareers Discounts Available

Be sure to check out the new www.cancercareers.org website for career opportunities. MEG members now receive a 15 percent discount for all employment postings. Use the code MEGAD when submitting your advertisement to receive this special rate. You can also sign-up for job alerts and refine a job search by a specific research area, i.e. epidemiology; prevention. Look on the right side of the website for these options.

To submit an announcement for consideration, please note:

Employment opportunities should be sent to cancercareers.org for posting consideration on that website. Please refer all questions regarding employment posting to
Custom​erService@CancerCareers.org.

Postings of a non-employment nature may still be sent to meg@aacr.org for review and possible future posting on the MEG Announcements.

Best regards from everyone at the AACR, and sincere appreciation for your
AACR-MEG Membership.